Symbiosis announces £1 million investment in analytical testing capability

July 2022:  Symbiosis Pharmaceutical Services (Symbiosis), an international contract manufacturing organisation (CMO) with headquarters in the UK, who specialise in providing GMP aseptic fill and finish services for biologic and small molecule pharmaceuticals to biotechnology and pharmaceutical companies worldwide, has announced a 1 million GBP (1.2 million Euros, 1.3 million USD) investment in its in-house analytical services capabilities.This investment will see the… Read More

Symbiosis announces successful completion of UK Research and Innovation (UKRI) project

Stirling, UK – Mar 2022: Symbiosis Pharmaceutical Services Ltd (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has announced the completion of a £1.3 million collaborative UKRI-funded project as part of the medicines manufacturing challenge.Symbiosis and The Cell and Gene Therapy Catapult (CGT Catapult) have successfully developed… Read More

Symbiosis announces expansion of capabilities with BSL-2 manufacturing upgrade

Stirling, UK – Jan, 2022: Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, has announced an expansion of its capabilities to handle novel and emerging treatments, such as viral based gene- and oncolytic-therapies.Headquartered in Stirling, UK, Symbiosis has completed a physical and regulatory upgrade to its existing manufacturing suites to enable… Read More

Symbiosis starts producing sevuparin for Modus Therapeutics’ future clinical development in sepsis/septic shock

We’re very proud to announce that Symbiosis is working with Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, to manufacture their sevuparin drug product, securing the supply for the Phase II clinical development in sepsis/septic shock and other conditions driven by systemic inflammation.Click here to find out more about this partnership:

Symbiosis announces successful MHRA audit and expanded facility at its Stirling, UK site

Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing Contract Manufacturing Organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals, and biopharmaceuticals, and headquartered in Stirling, UK, announces that it has successfully completed a Medicines and Healthcare products Regulatory Agency (MHRA) inspection of its newly commissioned warehouse and storage area.The company has been undertaking phased expansion to its manufacturing support capability, including the newly operational warehousing… Read More

Symbiosis is attending the Digital BIO International Convention 2021

This month our CEO, Colin MacKay, Head of Business Development, Helen-Caddy-Leach and key members of our Business Development team are excited to be attending the annual BIO International Convention, which will be held virtually this year as BIO Digital.The event brings together leaders in the global biotech industry to provide networking opportunities, educational resources to help drive your business, and the insights… Read More

Case Study: Advanced Therapies Apprenticeship Community (ATAC)

Building a workforce with the right skills is crucial and at Symbiosis we believe that having an unrivalled apprenticeship programme is undeniably worthwhile and mutually beneficial.With the help of the Advanced Therapies Apprenticeship Community (ATAC) our apprentice programme has become an integral part of our recruitment process and has allowed us to fully benefit from our apprentices – making them a much… Read More

Vaccine Success!

Amazing news for everyone with the confirmation that AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK by the MHRA, the UK medicines regulator, with the first doses being released today (Dec. 30th 2020) so that vaccinations may begin early in the New Year.As a key supplier of the AZD1222 vaccine to AstraZeneca for clinical trials, everyone at Symbiosis is tremendously proud to… Read More

Get In Touch.

By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.